Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Braintree, MA.

Microbot Medical Inc. (MBOT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Microbot Medical Inc. (MBOT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

The Webinar, Which is Suitable to All Stakeholders Interested in the Future of Endovascular Robotics, Will be Held on Wednesday, December 21, 2022, at 1:00pm ET

Microbot Medical Announces the Participation of a Key Opinion Leader in the Endovascular Robotics Space at the Next “Access-Ability Live by MBOT” Webinar Series

Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory Progress

Microbot Medical's Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Th e “ Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience

Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space

Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology

Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY® Robotic System

Growing SAB Roster Includes 11 KOLs from Across the U.S. , Europe, and Israel

Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe's Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board

HINGHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company's common stock (which includes pre-funded warrants to purchase 240,000 shares of common stock) at a purchase price of $4.89 per share of common stock (or $4.8899 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued to the investor unregistered series A preferred investment options and series B preferred investment options. The series A preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of five years following issuance. The series B preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of two years following issuance.

Microbot Medical Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company's common stock (which includes pre-funded warrants to purchase 240,000 shares of common stock) at a purchase price of $4.89 per share of common stock (or $4.8899 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor unregistered series A preferred investment options and series B preferred investment options. The series A preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of five years following issuance. The series B preferred investment options to purchase up to 1,022,495 shares of common stock have an exercise price of $4.64 per share and are immediately exercisable for a period of two years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about October 25, 2022, subject to the satisfaction of customary closing conditions.

Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY® Robotic System to ensure the Company remains fully aligned with the U.S. Food and Drug Administration (FDA) as it prepares for its Investigational Device Exemption (IDE) submission and first-in-human clinical trial with the system in 2023.

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY® Robotic System

HINGHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures. The study was performed by a team of seasoned Key Opinion Leaders (KOLs) in the endovascular space at a world-class MedTech research laboratory with FDA-required levels of planning, controlling, monitoring, and reporting (GLP standards), using porcine model.

Microbot Medical Completes GLP Animal Study for the LIBERTY® Robotic System

Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the Technology Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the Technology

Microbot Medical Receives Patent Allowance in Israel for the LIBERTY® Robotic System

Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market1 through the Expansion of Robotic Ecosystem for Endovascular Procedures

Microbot Medical Strengthens LIBERTY® Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices

Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience Award-Winning Interventional Radiologist in the NY Metro Area Adds Significant Depth and Experience

Microbot Medical Announce Strategic Addition to Scientific Advisory Board Appointment

Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System

Microbot Medical Enhances its Scientific Advisory Board (SAB) with its Newest Member Dr. Vincent Vidal

Company Continues to Achieve Primary Objectives for its LIBERTY® Robotic System in 2022 Company Continues to Achieve Primary Objectives for its LIBERTY® Robotic System in 2022

Microbot Medical to Review Recent Progress During H.C. Wainwright's 24th Annual Global Investment Conference

GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space

Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY® Robotic System

A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization

Microbot Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke

HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-leading research laboratory to conduct the Company's GLP pre-clinical trial. The comprehensive trial, which is anticipated to commence later this month, will be performed by a team of global leaders in the endovascular space at a state-of-the-art lab with FDA approved levels of planning, controlling, monitoring and reporting (GLP standards).

Microbot Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month

HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company's Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel.

Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons

HINGHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview of the Company and recent progress on Tuesday, April 12th at 8:45am ET.

Microbot Medical to Review Recent Progress During Needham's Virtual Healthcare Conference

Company Continues to Enhance Core Capabilities to Ensure Commercial and Financial Success Company Continues to Enhance Core Capabilities to Ensure Commercial and Financial Success

Microbot Medical Continues to Strengthen Management Team as Rachel Vaknin Promoted to Chief Financial Officer

ShiftPixy

Digital World Acquisition Corp

Insignia Systems

Reliance Global Group

These five top short squeeze stocks are among the stocks that are making positive moves today, as investors go cherry-picking for wins. The post Short Squeeze Stocks: PIXY, MBOT and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: PIXY, MBOT and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: ShiftPixy Tops List, Trump SPAC Rejoins

American Virtual Cloud Technologies

These five top short squeeze stocks are worth a close look from retail investors looking for opportunities in an otherwise down market. The post Short Squeeze Stocks: ISIG, PIXY and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: ISIG, PIXY and 3 Others Experts Think Are Ready to Pop

Microbot Medical is a $50 million pre-revenue company that developed and owns its patented LIBERTY Robotics System. On December 27, 2021, the company signed a collaboration agreement with Stryker Corporation. Stryker has a $100 billion market capitalization and is dominant in the medical devices field.

News for Microbot Medical Stock (MBOT)